<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00367757</url>
  </required_header>
  <id_info>
    <org_study_id>AF06002AF</org_study_id>
    <nct_id>NCT00367757</nct_id>
  </id_info>
  <brief_title>STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial</brief_title>
  <official_title>Open, Prospective, Randomized Trial Comparing Trigger vs Substrate vs Hybrid Approaches for AF Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient Population: Patients with AF that is symptomatic and refractory to at least one
      antiarrhythmic medication. Patients must have AF that is paroxysmal (&gt;4 episodes within 6
      months, two episodes &gt;6 hours within 1 year) or persistent (sustained episode &lt;6 months
      terminated by cardioversion or drug).

      Purpose: To compare a trigger-based technique (pulmonary vein isolation) to a substrate-based
      technique (high-frequency, fractionated EGMs) to a combined approach for AF ablation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventions: Patients will be randomized to either wide circumferential pulmonary vein
      isolation (&quot;trigger&quot;) or ablation of high-frequency, fractionated electrograms during AF
      (&quot;substrate&quot;), or a hybrid approach combining trigger and substrate. Both techniques will be
      performed with NavX mapping system and a standardized ablation catheter. Endpoint of PVI will
      be isolation of all four PVs documented by circular catheter. Endpoint for substrate-based
      ablation will be termination and noninducibility of AF. Up to 2 procedures will be allowed
      within 6 months. A 2 month blanking period will be allowed after each procedure during which
      early recurrences will not be counted.

      Outcomes:

        -  Recurrence of atrial fibrillation or other atrial tachycardia at 3, 6, and 12 months
           post-initial procedure.

        -  Recurrence will be defined by symptoms and/or ECG/Holter data showing AF &gt; 2 mins

        -  Occurrence of adverse events in each group post-procedure.

        -  Quality of life assessment at 6 and 12 months post-initial procedure.

      Followup:

        -  3, 6, and 12 months post-initial procedure.

        -  Clinical data, ECG, Holter, loop recorder at baseline and at each visit.

        -  QOL at baseline, 3, 6 and 12 months post-initial procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from atrial fibrillation at 3 months post-first ablation procedure off antiarrhythmic medications.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from atrial fibrillation at 6 and 12 months post-first ablation procedure off antiarrhythmic medications.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial fibrillation on or off antiarrhythmic medications at 3, 6 and 12 months post-first ablation procedure.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from atrial fibrillation and other atrial arrhythmias at 3, 6 and 12 months post-first ablation procedure.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri-procedural complications including stroke, PV stenosis, cardiac perforation, esophageal injury, and death.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration at ablation.</measure>
    <time_frame>At intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopy time at ablation.</measure>
    <time_frame>At intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measurements (SF-36) at baseline, 3, 6 and 12 months post-first procedure.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>PVI group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Trigger-based ablation guided by pulmonary vein antrum isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CFAE group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Substrate-based ablation using an approach targeting CFAEs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combined trigger and substrate based approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablate AF triggers via PVI</intervention_name>
    <description>Trigger-based ablation guided by pulmonary vein antrum isolation</description>
    <arm_group_label>PVI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Substrate via CFAEs</intervention_name>
    <description>Substrate-based ablation using an approach targeting CFAEs</description>
    <arm_group_label>CFAE group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combined approach for AF ablation</intervention_name>
    <description>Combined trigger and substrate based approach</description>
    <arm_group_label>Combined group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 18 or greater.

          -  &quot;high burden&quot; of paroxysmal atrial fibrillation or persistent atrial fibrillation

          -  candidates for AF ablation based on AF that is symptomatic and refractory to at least
             one antiarrhythmic medication.

          -  At least one episode of AF must have been documented by ECG or Holter within 12 months
             of randomization in the trial.

          -  continuous anticoagulation with warfarin (INR 2-3) for &gt;4 weeks prior to the ablation.

          -  Patients must be able and willing to provide written informed consent to participate
             in the clinical trial.

        Exclusion Criteria:

          -  chronic atrial fibrillation.

          -  Patients with AF felt to be secondary to an obvious reversible cause.

          -  inadequate anticoagulation as defined in the inclusion criteria.

          -  left atrial thrombus or spontaneous echo contrast on TEE prior to procedure.

          -  contraindications to systemic anticoagulation with heparin or coumadin.

          -  previously undergone atrial fibrillation ablation.

          -  left atrial size &gt; 55 mm.

          -  Patients who are or may potentially be pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul Verma, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southlake Regional Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heaert Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials Inc - Royal Jubilee</name>
      <address>
        <city>Victoria</city>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Santa Maria</name>
      <address>
        <city>Bari</city>
        <state>Apulia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale Ca'Foncello</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <state>Haukeland</state>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2006</study_first_submitted>
  <study_first_submitted_qc>August 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2006</study_first_posted>
  <last_update_submitted>July 30, 2009</last_update_submitted>
  <last_update_submitted_qc>July 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Atul Verma</name_title>
    <organization>Southlake Regional Health Centre, Southlake, Canada</organization>
  </responsible_party>
  <keyword>paroxysmal atrial fibrillation</keyword>
  <keyword>persistent atrial fibrillation</keyword>
  <keyword>high burden of atrial fibrillation</keyword>
  <keyword>atrial fibrillation ablation</keyword>
  <keyword>Pulmonary vein isolation</keyword>
  <keyword>AF trigger</keyword>
  <keyword>complex fractionated electrograms</keyword>
  <keyword>CFE</keyword>
  <keyword>CFAE</keyword>
  <keyword>complex fractionated atrial electrograms</keyword>
  <keyword>refractory antiarrhythmic medication</keyword>
  <keyword>PVAI</keyword>
  <keyword>Ensite NavX</keyword>
  <keyword>NavX</keyword>
  <keyword>CoolPath catheter</keyword>
  <keyword>irrigated ablation catheter</keyword>
  <keyword>high burden of paroxysmal or persistent atrial fibrillation</keyword>
  <keyword>candidates for AF ablation</keyword>
  <keyword>symptomatic AF</keyword>
  <keyword>AF is refractory to at least one antiarrhythmic medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

